Therapeutic efficacy and mechanism of CD73-TGFβ dual-blockade in a mouse model of triple-negative breast cancer

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

FDA Approval Summary: Atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1

(2020) Preeti Narayan et al.   CLINICAL CANCER RESEARCH

A Potent Pan-TGFβ Neutralizing Monoclonal Antibody Elicits Cardiovascular Toxicity in Mice and Cynomolgus Monkeys

(2020) Mayur S Mitra et al.   TOXICOLOGICAL SCIENCES

The Landscape of Targeted Therapies in TNBC

(2020) Elena Vagia et al.   Cancers

Targeting CD73 to augment cancer immunotherapy

(2020) Meejeon Roh et al.   CURRENT OPINION IN PHARMACOLOGY

TGFβ biology in cancer progression and immunotherapy

(2020) Rik Derynck et al.   Nature Reviews Clinical Oncology

Dual mechanisms of novel CD73-targeted antibody and antibody-drug conjugate in inhibiting lung tumor growth and promoting antitumor immune-effector function

(2020) Rui Jin et al.   MOLECULAR CANCER THERAPEUTICS

Tissue Immune Profile: A Tool to Predict Response to Neoadjuvant Therapy in Triple Negative Breast Cancer

(2020) Bruna Cerbelli et al.   Cancers

Direct and Indirect Regulators of Epithelial-Mesenchymal Transition (EMT)-mediated Immunosuppression in Breast Carcinomas

(2020) Anushka Dongre et al.   Cancer Discovery

Mesenchymal Stromal Cells Derived from Normal Cervix and Cervical Cancer Tumors Increase CD73 Expression in Cervical Cancer Cells Through Transforming Growth Factor-Beta 1 Production

(2019) Luis Roberto Ávila-Ibarra et al.   STEM CELLS AND DEVELOPMENT

CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer

(2019) Bruna Cerbelli et al.   VIRCHOWS ARCHIV

TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis

(2018) Xiaodan Xu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

(2018) Julius Strauss et al.   CLINICAL CANCER RESEARCH

Chemotherapy induces enrichment of CD47+/CD73+/PDL1+immune evasive triple-negative breast cancer cells

(2018) Debangshu Samanta et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

(2018) Yan Lan et al.   Science Translational Medicine

Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy

(2018) Rajani Ravi et al.   Nature Communications

Cervical cancer cells produce TGF-β1 through the CD73-adenosine pathway and maintain CD73 expression through the autocrine activity of TGF-β1

(2018) Rosario García-Rocha et al.   CYTOKINE

Pharmacological and immunological targeting of tumor mesenchymalization

(2017) Justin M. David et al.   PHARMACOLOGY & THERAPEUTICS

Role of transforming growth factor-β1 in triple negative breast cancer patients

(2017) Mingxia Zhang et al.   International Journal of Surgery

Pathological expression of tissue factor confers promising antitumor response to a novel therapeutic antibody SC1 in triple negative breast cancer and pancreatic adenocarcinoma

(2017) Xuesai Zhang et al.   Oncotarget

Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action

(2016) James C. Geoghegan et al.   mAbs

CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer

(2015) Martin Turcotte et al.   CANCER RESEARCH

Robust enumeration of cell subsets from tissue expression profiles

(2015) Aaron M Newman et al.   NATURE METHODS

A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer

(2014) ALLEN COHN et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Role of TGF-β Signaling in Generation of CD39+CD73+Myeloid Cells in Tumors

(2014) Sergey V. Ryzhov et al.   JOURNAL OF IMMUNOLOGY

Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs

(2013) B. Allard et al.   CLINICAL CANCER RESEARCH

CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer

(2013) S. Loi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Expression and clinical significance of CD73 and hypoxia-inducible factor-1α in gastric carcinoma

(2013) Xiao-Xia Lu   WORLD JOURNAL OF GASTROENTEROLOGY

Stat3 and Gfi-1 Transcription Factors Control Th17 Cell Immunosuppressive Activity via the Regulation of Ectonucleotidase Expression

(2012) Fanny Chalmin et al.   IMMUNITY

High expression of CD73 as a poor prognostic biomarker in human colorectal cancer

(2012) Xian-Rui Wu et al.   JOURNAL OF SURGICAL ONCOLOGY

The basics of epithelial-mesenchymal transition

(2009) Raghu Kalluri et al.   JOURNAL OF CLINICAL INVESTIGATION

Pattern of metastatic spread in triple-negative breast cancer

(2008) Rebecca Dent et al.   BREAST CANCER RESEARCH AND TREATMENT